RxDoctor Payments Data

Jesse Clark, MD

Infectious Disease · Los Angeles, CANPI 1811166572

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,510 of the $7,384 with a category attached, or 74.6%. Gilead accounts for 98.7% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2024 at $7,029 and has fallen 96.3% since, to $258 in 2025.

$7,384in general payments, 2019–2025

Across 21 payments — averaging $351.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$7K
  • Viiv Healthcare Company$97
$1,968,035in research payments, 2019–2025

Across 63 payments — averaging $31,239 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$2M

What the payments were for

  • Consulting fees$5,51075%
  • Travel & lodging$1,29318%
  • Food & beverage$5808%

General payments by program year

20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead17$7,287
Viiv Healthcare Company4$97

How this compares

$7,384 in reported general payments places this provider in the 85th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$22,593
Medicare patients
70
Services billed
171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →